Herbs (Global Traditional) · Amazonian
Smilax officinalis
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Smilax officinalis is an Amazonian plant containing saponins and phenolic compounds that demonstrate anti-inflammatory and antiviral properties. The plant's bioactive compounds work by inhibiting inflammatory pathways and viral replication mechanisms in preliminary studies.
Smilax officinalis, commonly known as sarsaparilla, is a perennial climbing vine native to Central and South America, belonging to the Smilacaceae family. The medicinal rhizome (root) is harvested, dried, and extracted using solvents like methanol or ethyl acetate to yield bioactive fractions containing steroidal saponins, flavonoids, and polyphenols.
Clinical evidence for Smilax officinalis is extremely limited, with no large-scale RCTs or PubMed-listed trials specifically on this species identified. A small clinical report on related S. glabra for syphilis (n=42) showed 61.90% negative conversion versus 23.81% in controls, but lacked placebo control. Most evidence derives from preclinical studies and traditional use reports.
No standardized clinical dosages are established for Smilax officinalis due to lack of human trials. Traditional preparations use aqueous extracts of unspecified doses, while preclinical studies utilized methanol/ethyl acetate extracts without detailed concentrations. Standardization typically targets steroidal saponins (5-15% in rhizome) or flavonoids. Consult a healthcare provider before starting any new supplement.
Smilax officinalis (sarsaparilla) is not consumed as a caloric food source; it is used primarily as a medicinal root decoction or extract. The root is valued for its bioactive phytochemical content rather than macronutrient contribution. Key compounds include: • **Steroidal saponins** (1–3% dry weight): sarsasapogenin, smilagenin, sarsaparilloside, and parillin — these are the principal bioactive constituents responsible for anti-inflammatory and hormonal-modulating activity; oral bioavailability is limited due to poor intestinal absorption of intact saponins, though partial hydrolysis to aglycones (sapogenins) improves uptake. • **Flavonoids**: astilbin (estimated 0.1–0.5% dry weight), isoastilbin, neoastilbin, and engeletin — these contribute antioxidant and anti-inflammatory properties; astilbin has moderate oral bioavailability (~20–30% in rodent models). • **Phenylpropanoids and stilbenes**: trans-resveratrol and related derivatives in trace amounts (<0.01%). • **Phytosterols**: beta-sitosterol, stigmasterol, and diosgenin (collectively ~0.2–0.8% dry weight); bioavailability of phytosterols is generally low (2–5% absorption). • **Minerals**: the root contains moderate levels of iron (approximately 3–8 mg/100 g dry weight), chromium (trace), manganese (~1–3 mg/100 g), and zinc (~1–2 mg/100 g); aluminum, copper, and selenium are present in trace amounts. Mineral bioavailability may be reduced by saponin and tannin binding. • **Dietary fiber**: the crude root contains roughly 30–45% total dietary fiber (dry weight), predominantly insoluble cellulose and hemicellulose; this fiber is not typically consumed when prepared as a decoction/tea. • **Protein**: approximately 2–5% crude protein (dry weight), nutritionally insignificant in typical medicinal doses. • **Carbohydrates**: approximately 40–55% dry weight, largely starch and structural polysaccharides. • **Tannins**: condensed tannins at approximately 1–2% dry weight, contributing astringency and potential iron-chelation effects that may reduce mineral absorption. • **Vitamins**: no significant vitamin content has been documented at pharmacologically meaningful levels. • **Typical medicinal dose**: 1–4 g dried root or 2–8 mL of a 1:5 tincture, delivering roughly 10–120 mg total saponins and 1–5 mg astilbin per dose. At standard doses, caloric and macronutrient contributions are negligible.
Smilax officinalis contains saponins and phenolic compounds that inhibit α-glucosidase enzyme activity, potentially reducing post-meal blood glucose spikes. The plant's anti-inflammatory effects appear to work through modulation of inflammatory cytokines and pathways involved in arthritis progression. Antiviral activity occurs through interference with viral replication processes, showing IC50 values of 31.3-62.5 μg/mL against HSV-1 and respiratory syncytial virus.
Current evidence for Smilax officinalis comes primarily from preclinical studies and in vitro research. Anti-inflammatory effects have been demonstrated in rat adjuvant arthritis models, though specific sample sizes and study durations were not detailed in available data. Antiviral testing has been conducted in laboratory cell cultures, showing measurable inhibitory concentrations against HSV-1 and RSV. Human clinical trials are needed to establish therapeutic efficacy and optimal dosing protocols.
Safety data for Smilax officinalis in humans is limited due to lack of comprehensive clinical studies. As with many Amazonian plants, potential interactions with prescription medications, particularly blood sugar-lowering drugs, should be considered given its α-glucosidase inhibitory activity. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals with autoimmune conditions should consult healthcare providers before use given the plant's immune system effects.
